Drug Trial Radar · NCT07520240
ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jan 31, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Interventional AnalgesiX Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.
Conditions
- Facet Joint Pain
Interventions
ITX24-01Drug
Fluoroscopy guided local administration by the medial branch block (MBB) route. Dosage form: liquid. Frequency of administration: once (single dose).
Normal Saline (0.9% NaCl)Drug
Placebo (negative control). Dosage form: liquid. Frequency of administration: once (single dose).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint painTime frame: During the screening period, on the day of ITX24-01 administration, and up to 6 weeks of follow-up.
- Tolerability of ITX24-01 or placebo delivered locally by the medial branch block (MBB) route in adult participants with severe chronic zygapophysial joint painTime frame: At pre-specified time points up to 6 hours after administration of the investigational medicinal product (IMP).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sydney Pain Management Centre
Wahroonga, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.